EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fudala, P. J
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fudala, P. J
Evidence-Based Medicine 2003; 8:150
© 2003 BMJ Publishing Group Ltd.

Therapeutics

Buprenorphine improved treatment retention in patients with heroin dependence

Kakko J, Svanborg KD, Kreek MJ, et al.1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.Lancet 2003;361:662–8[CrossRef][Medline]

QUESTION: In patients with heroin dependence, is buprenorphine added to intensive cognitive behavioural therapy effective?

Key Words: buprenorphine • heroin dependence • narcotic antagonists • psychotherapy (group)

The first 150 words of the full text of this article appear below.

Design
Randomised (allocation concealed*), blinded {patients, clinicians and data collectors}{dagger},* placebo controlled trial with follow up at 1 year.

Setting
The chemical dependence unit of an addiction centre in Stockholm, Sweden.

Patients
40 patients >=20 years of age (mean age 30 y, 73% men) with an opiate dependence who were seeking admission for medically assisted heroin withdrawal and had >=1 year of heroin dependence (DSM-IV criteria). Exclusion criteria were eligibility for methadone maintenance treatment in Sweden (>=4 y of multiple daily heroin use objectively documented in hospital records and >=3 unsuccessful attempts in abstinence oriented treatment); codependence on alcohol, amphetamines, cannabinoids, or benzodiazepines; neurological disorders; dementia; cognitive impairment; psychosis; or other psychiatric disorder (unless the patient was stable and on treatment not contraindicated to buprenorphine). All patients were included in the analysis.

Intervention
20 patients were allocated to sublingual buprenorphine, 16 mg, for 12 months, with >=6 months supervised daily . . . [Full text of this article]

Paul J Fudala, PhD

VA Medical Center/University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania, USA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 by the BMJ Publishing Group Ltd.